AQP4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3178559	1.00	1/20
SCHEMBL3379803	0.70	1/20
SCHEMBL3178619	0.63	1/20
SCHEMBL7553959	0.61	1/20
SCHEMBL7348856	0.60	1/20
SCHEMBL8127812	0.60	1/20
SCHEMBL8554147	0.60	1/20
SCHEMBL9963857	0.58	1/20
SCHEMBL1924051	0.57	1/20
SCHEMBL10406072	0.57	1/20
SCHEMBL1075622	0.57	1/20
SCHEMBL8157997	0.57	1/20
SCHEMBL11591966	0.56	1/20
SCHEMBL17175811	0.55	1/20
SCHEMBL12614021	0.55	1/20
SCHEMBL29199014	0.55	1/20
SCHEMBL14096368	0.53	1/20
SCHEMBL16186309	0.53	1/20
SCHEMBL12020893	0.53	1/20
SCHEMBL23778469	0.53	1/20

Clinical trials — most relevant to AQP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis	PHASE4	ACTIVE_NOT_RECRUITING
Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)	PHASE4	COMPLETED
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	PHASE3	COMPLETED
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders	PHASE2/PHASE3	COMPLETED
Ofatumumab in AQP4-IgG Seropositive NMOSD	PHASE1/PHASE2	RECRUITING
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)	PHASE2	ACTIVE_NOT_RECRUITING
Hematopoietic Stem Cell Transplant in Devic's Disease	PHASE1/PHASE2	COMPLETED
OCS-05 in Patients With Optic Neuritis	PHASE2	COMPLETED
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders	PHASE2	ACTIVE_NOT_RECRUITING
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	PHASE2	UNKNOWN
A Study of HBM9161 in NMOSD Patients	PHASE1	COMPLETED
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders	PHASE1	RECRUITING
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD	nan	RECRUITING
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital	nan	COMPLETED
Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected	nan	RECRUITING
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset	nan	UNKNOWN
Optic Neuritis Differential Diagnosis Study	nan	UNKNOWN
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve	nan	UNKNOWN
Scrambler Trial for Pain in NMOSD	nan	COMPLETED
Neuroimaging Risk of Postoperative Delirium	nan	UNKNOWN
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder	nan	RECRUITING
Assessment of Serum FAM19A5 Level in Egyptian Patients With Neuromyelitis Optica Spectrum Disorder	nan	UNKNOWN
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period	nan	COMPLETED
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis	nan	NOT_YET_RECRUITING
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders	nan	UNKNOWN
Pathologic-MRI Findings in Atypical IIDD	nan	COMPLETED
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies	nan	RECRUITING
A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil	nan	UNKNOWN
Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AQP4 binder may also engage these)

Protein	Name	Similarity
O77750	—	1.000	O77750 →
Q923J4	—	1.000	Q923J4 →
P47863	—	1.000	P47863 →
Q5I4F9	—	1.000	Q5I4F9 →
P55088	—	1.000	P55088 →
Q8LFP7	—	0.995	Q8LFP7 →
Q40746	—	0.993	Q40746 →
P29975	—	0.991	P29975 →
Q6Z2T3	—	0.991	Q6Z2T3 →
Q9FIZ9	—	0.991	Q9FIZ9 →
Q8VZW1	—	0.990	Q8VZW1 →
Q9WTY0	—	0.990	Q9WTY0 →
G5CTG2	—	0.990	G5CTG2 →
Q9ATN2	—	0.990	Q9ATN2 →
Q8W036	—	0.989	Q8W036 →
AQP1	Aquaporin-1	0.989	landscape →
Q0DK16	—	0.988	Q0DK16 →
Q5R819	—	0.988	Q5R819 →
Q9ATN4	—	0.988	Q9ATN4 →
P50501	—	0.987	P50501 →
Q13520	—	0.987	Q13520 →
Q9SAI4	—	0.987	Q9SAI4 →
P47865	—	0.987	P47865 →
Q9ZVX8	—	0.987	Q9ZVX8 →
Q9N2J4	—	0.986	Q9N2J4 →
Q6PQZ1	—	0.986	Q6PQZ1 →
Q8C4A0	—	0.986	Q8C4A0 →
Q19KC1	—	0.986	Q19KC1 →
Q02013	—	0.986	Q02013 →
Q866S3	—	0.986	Q866S3 →